We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald
Read MoreHide Full Article
Nektar Therapeutics (NKTR - Free Report) announced that it has signed an agreement to grant Daiichi Sankyo Europe the exclusive rights to market Onzeald (etirinotecan pegol) in Europe (EEA), Switzerland and Turkey.
Onzeald, formerly NKTR-102, is being developed for the treatment of patients with advanced breast cancer who have a history of brain metastases. The company has completed a phase III study – BEACON – in women with locally recurrent or metastatic breast cancer, who were previously treated with anthracycline, taxane and Xeloda (capecitabine) therapies.
As per the terms of the agreement, Nektar will receive an upfront payment of $20 million from Daiichi Sankyo. In addition, the company is entitled to receive additional milestone payments worth $60 million, based upon the achievement of European regulatory milestones and sales of Onzeald in Europe. It will also earn double-digit royalties on net sales in Europe. Nektar retains rights to market Onzeald in the U.S. and the rest of the world.
The company intends to submit a Marketing Authorisation Application (MAA) in the EU this month for a conditional approval of Onzeald for the treatment of patients with advanced breast cancer and brain metastases. We note that last month, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) granted accelerated assessment procedure for the planned regulatory filing.
In order to support an MAA filling, Nektar will conduct a confirmatory study on Onzeald. The randomized phase III study will evaluate Onzeald, in comparison with a single-agent chemotherapy of physician's choice (TPC), in patients (n~350) with advanced breast cancer and brain metastases. The primary endpoint of the study is the overall survival. Data from the study will also be used for filing for a New Drug Application (NDA) for Onzeald in the U.S.
It has been found that approximately 10–30% of patients with advanced breast cancer are diagnosed with brain metastases.
Nektar currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Pfizer Inc. (PFE - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Nektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald
Nektar Therapeutics (NKTR - Free Report) announced that it has signed an agreement to grant Daiichi Sankyo Europe the exclusive rights to market Onzeald (etirinotecan pegol) in Europe (EEA), Switzerland and Turkey.
Onzeald, formerly NKTR-102, is being developed for the treatment of patients with advanced breast cancer who have a history of brain metastases. The company has completed a phase III study – BEACON – in women with locally recurrent or metastatic breast cancer, who were previously treated with anthracycline, taxane and Xeloda (capecitabine) therapies.
As per the terms of the agreement, Nektar will receive an upfront payment of $20 million from Daiichi Sankyo. In addition, the company is entitled to receive additional milestone payments worth $60 million, based upon the achievement of European regulatory milestones and sales of Onzeald in Europe. It will also earn double-digit royalties on net sales in Europe. Nektar retains rights to market Onzeald in the U.S. and the rest of the world.
The company intends to submit a Marketing Authorisation Application (MAA) in the EU this month for a conditional approval of Onzeald for the treatment of patients with advanced breast cancer and brain metastases. We note that last month, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) granted accelerated assessment procedure for the planned regulatory filing.
In order to support an MAA filling, Nektar will conduct a confirmatory study on Onzeald. The randomized phase III study will evaluate Onzeald, in comparison with a single-agent chemotherapy of physician's choice (TPC), in patients (n~350) with advanced breast cancer and brain metastases. The primary endpoint of the study is the overall survival. Data from the study will also be used for filing for a New Drug Application (NDA) for Onzeald in the U.S.
It has been found that approximately 10–30% of patients with advanced breast cancer are diagnosed with brain metastases.
Nektar currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Pfizer Inc. (PFE - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>